Abbott starts trial on deep brain stimulation for depressive disorder
Abbott Laboratories has initiated a clinical trial to evaluate the use of the company's deep brain stimulation system to manage treatment-resistant depression, a.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Abbott Laboratories has initiated a clinical trial to evaluate the use of the company's deep brain stimulation system to manage treatment-resistant depression, a.
Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.
Smoking cigarettes may protect humans from neurodegeneration and prevent the accumulation of a key Parkinson’s-associated protein in the brain, new research on mice.
US-based Neurocrine Biosciences’ trial drug for treating schizophrenia reduced the severity of the disease symptoms in a mid-stage study of 210 adult participants.
Walgreens Boots Alliance Inc., the second-largest pharmacy store chain in the US has bagged a $100 million government funding to expand its clinical.
Pfizer Inc.’s vaccine trials on patients aged 18 and older with chronic respiratory diseases show a consistent safety profile and “strong neutralizing responses,”.
Lykos Therapeutics’s ecstasy drug or midomafetamine capsules for the treatment of post-traumatic stress disorder in adults was rejected by the US drug regulatory.
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.
Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.
The US drug regulator has granted permission for expanded use of British pharmaceutical company, GSK Plc’s endometrial cancer drug.